Mark James McKeage

Mark James McKeage

Auto-generated profile, based on publicly available information

Mark James McKeage

Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PLPrimo N. Lara
Primo N. Lara
JDJean-Yves Douillard
Jean-Yves Douillard
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
JPJoachim von Pawel
Joachim von Pawel
MMMark J. McKeage
Mark J. McKeage
GSGiorgio Scagliotti
Giorgio Scagliotti
Purpose: This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non–small-cell lung cancer (NSCLC) versus chemotherapy alone. Patients and Methods: Patients with advanced stage IIIB or IV NSCLC, stratified by sex and tumor histology, were randomly assigned 1:1 to paclitaxel (200 mg/m2) and carboplatin (area under the curve, 6.0) with or without ASA404 (1,800 mg m2), given intravenously once every 3 weeks for six cycles followed by maintenance ASA404 or placebo. Primary end point was overall survival (OS); secondary end points included overall response rate (ORR) and progression-free survival (PFS). Results: One thousand two hundred ninety-nine patients were randomly assigned. The trial was stopped for futility at interim analysis. At final analysis, there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535). Similarly, no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata. Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0). Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms. Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm. Conclusion: The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.

1 October 1995 in Drug Safety
Verified
Journal Article
Closed access
PDF file
MMMark J. McKeage
Mark J. McKeage

1 October 2002 in Coordination Chemistry Reviews
Verified
Journal Article
Closed access
MMMark J McKeage
Mark J McKeage
LMLenushka Maharaj
Lenushka Maharaj
SBSusan J Berners-Price
Susan J Berners-Price

6 November 2000 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
MMMark J. McKeage
Mark J. McKeage
SBSusan J. Berners-Price
Susan J. Berners-Price
PGPeter Galettis
Peter Galettis
RBRichard J. Bowen
Richard J. Bowen
WBWandy Brouwer
Wandy Brouwer
BBBruce C. Baguley
Bruce C. Baguley

1 February 2008 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
JLJohnson J. Liu
Johnson J. Liu
PGPeter Galettis
Peter Galettis
AFAlistair Farr
Alistair Farr
LMLenushka Maharaj
Lenushka Maharaj
HSHasitha Samarasinha
Hasitha Samarasinha
MMMark J. McKeage
Mark J. McKeage

1 February 2000 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
DSD Screnci
D Screnci
MMM J McKeage
M J McKeage
PGP Galettis
P Galettis
THT W Hambley
T W Hambley
BPB D Palmer
B D Palmer
BBB C Baguley
B C Baguley
Previous work has shown platinum drugs to differ in their effects on the peripheral nervous system. To test whether their differential toxicity was due to differences in their partitioning into the peripheral nervous system, we correlated the hydrophobicity, reactivity, tissue accumulation and neurotoxicity of a series of eight platinum analogues. Neurotoxicity was detected by measuring sensory nerve conduction velocity (SNCV) in Wistar rats treated twice per week at the maximum tolerated dose. Tissue platinum concentrations were measured by inductively coupled plasma mass spectrometry. Hydrophobicity (log P) was measured using an octanol-aqueous shake-flask method. The half-life of platinum drug binding to plasma proteins in vitro was determined. The cumulative dose causing altered SNCV ranged from 15 to > 2050 μmol kg–1. Ranking of the compounds by their neurotoxic potency in rats (oxaliplatin >R,R -(DACH)PtC4> ormaplatin >S,S -(DACH)PtCl4>S,S -(DACH)Pt oxalato > cisplatin > carboplatin > JM216) correlated with the frequency of neurotoxicity in patients (r> 0.99;P< 0.05). Ranking the compounds by their peripheral nerve accumulation was cisplatin > carboplatin > oxaliplatin >R,R -(DACH)PtCl4≈S,S -(DACH)PtCl4and did not correlate with neurotoxicity. Log P ranged from – 2.53 to –0.16 but did not correlate with neurotoxicity. Log P correlated inversely with platinum accumulation in dorsal root ganglia (r2= 0.99;P = 0.04), sural nerve (r2= 0.85;P = 0.025), sciatic nerve (r2= 0.98;P = 0.0012), spinal cord (r2= 0.97, P = 0.018) and brain (r2= 0.98, P = 0.001). Reactivity correlated with neurotoxicity potency in rats (r2= 0.89, P = 0.0005) and with the frequency of neurotoxicity in patients (r2= 0.99, P = 0.0002). The hydrophilicity of platinum drugs correlates with platinum sequestration in the peripheral nervous system but not with neurotoxicity. Differences in the reactivity of platinum complexes accounts for some of the variation in their neurotoxicity. © 2000 Cancer Research Campaign